Albumedix Limited

University of Oslo

Tillotts Pharma Ag

Novozymes Biopharma Dk A/s

Universitetet | Oslo

Novozymes Biopharma Dic A/s

Albumedix A/s

Jan Terje Andersen

Inger Sandlie

Jason Cameron

Andrew Plumridge

Esben Peter Friis

Darrell Sleep

Karen Ann Delahay

Jens Erik Nielsen

Stian Foss

Malin Bern

Esther Maria Furrer

Leslie Evans

Steven Athwal

Elizabeth Allan

Bjorn Dalhus

The present invention relates to antibodies which bind to TNFα and exhibit modified FcRn-binding. The antibodies of the invention have good effector functions and/or pharmacokinetic properties.

Antibody variants

The present invention relates to compositions and methods for antibody-mediated therapy. In particular, provided herein are engineered immunoglobulins with altered half-life.

Engineered immunoglobulins with altered FcRn binding

The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Albumin variants

The present invention relates to albumin variants with an improved affinity for the neonatal Fc receptor (FcRn) and uses thereof, and in particular to the use of such albumin variants as carriers for immunogens. In some embodiments, the present invention relates to vaccines (e.g., vaccines for mucosal delivery) comprising albumin/immunogen fusion proteins.

Albumin variants and uses thereof

The present invention relates to variants of a parent albumin having altered plasma half-life compared with the parent albumin. The present invention also relates to fusion polypeptides and conjugates comprising said variant albumin.

The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides.

Albumin derivatives and variants

Variants of a parent albumin having altered plasma half-life compared with a parent albumin are described. Fusion polypeptides and conjugates including the variant albumin are also described. Embodiments include, but are not limited to, a polypeptide which is a variant of albumin, including one or more alterations at one or more positions corresponding to 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119 and 120 in SEQ ID NO: 2.

Growing community of inventors

Oslo, Norway

Jan Terje Andersen